Peptides & the FDA review: your questions, answered

Yes - LL-37 is a natural human antimicrobial peptide. That doesn't make a manufactured, injected version approved or proven; it remains investigational.¹

LL-37 is not an FDA-approved drug and has no cleared compounding pathway. It was removed from Category 2 in April 2026 but is not on the July 2026 agenda; a later review is expected.^{2 3}

No. The strongest KPV evidence comes from animal and cell studies, most notably a 2008 mouse colitis study. There are no large human trials establishing that KPV is safe and effective for any condition.⁴

The FDA-evaluated use listed for KPV is wound healing and inflammatory conditions.⁵

KPV is not an FDA-approved drug and has no cleared compounding pathway. It was placed in Category 2 of the interim 503A list, then removed in April 2026 and referred to the July 2026 advisory committee. Removal from Category 2 did not add it to the approved list.^{5 6 7}

Not on the July 2026 agenda. A later review is anticipated (reported as early 2027); no official FDA date was confirmed as of July 2026.^{8 9}

Yes - as a topical cosmetic ingredient, which is regulated differently from injectable drugs. The compounding review concerns the injectable form.⁸

Topical GHK-Cu is sold as a cosmetic ingredient. The injectable form is not an FDA-approved drug and has no cleared compounding pathway; it was removed from Category 2 (injectable) in April 2026 but is not on the July 2026 agenda.^{9 8}

Peppies was founded by an entrepreneur with a track record of turning confusing consumer problems into organized public action. We don’t sell peptides, and we’re transparent about the incentive: we’d benefit only from a legal, regulated market — the same outcome that makes people safer — not from today’s grey market. Full disclosure is here.

No. Peppies is an independent private venture, not affiliated with, endorsed by, or acting on behalf of the FDA or any government body.